FTC Sues Endo, Impax, Amneal For Antitrust Pact To Monopolize Opana ER Opioids Market

(January 29, 2021, 2:12 PM EST) -- WASHINGTON, D.C. — The U.S. Federal Trade Commission on Jan. 25 filed a civil antitrust complaint against Endo Pharmaceuticals Inc., Impax Laboratories LLC and Amneal Pharmaceuticals Inc., alleging that the defendants’ 2017 agreement sought to eliminate competition for the opioid oxymorphone ER....

Attached Documents

Related Sections